Skip to main content
68°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Veracyte, Inc. - Common Stock
(NQ:
VCYT
)
27.24
+0.16 (+0.59%)
Streaming Delayed Price
Updated: 10:45 AM EDT, Jul 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Veracyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
August 15, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Second Quarter 2023 Financial Results
August 08, 2023
From
Veracyte, Inc.
Via
Business Wire
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
August 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
July 19, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
June 20, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
June 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
May 31, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END
Via
FinancialNewsMedia
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
May 25, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
May 24, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
May 23, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
May 12, 2023
From
Veracyte, Inc.
Via
Business Wire
A New Groundbreaking Tool to Detect Colon Cancer Earlier
May 10, 2023
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This...
Via
PressReach
Veracyte Announces First Quarter 2023 Financial Results
May 04, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
May 04, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
May 03, 2023
From
Veracyte, Inc.
Via
Business Wire
New Artificial Intelligence Tool Can Diagnose Colon Cancer
May 03, 2023
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and...
Via
PressReach
Topics
Artificial Intelligence
Death
Veracyte Announces Release of Inaugural ESG Report
May 03, 2023
From
Veracyte, Inc.
Via
Business Wire
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
May 02, 2023
From
Veracyte, Inc.
Via
Business Wire
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
May 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
April 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
April 27, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
April 17, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
April 13, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
April 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
March 15, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
March 11, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
February 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
February 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
February 15, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
February 13, 2023
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.